grant

The translocator protein (TSPO) as a novel target for the treatment of Alzheimers disease [ 2010 - 2012 ]

Also known as: Novel treatment approach for Alzheimers disease

Funded by National Health and Medical Research Council
Managed by The University of Sydney
Managed by University of Sydney
Provided by   National Health and Medical Research Council

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/632876]

Researchers: Prof Lars Ittner (Principal investigator) ,  Prof Michael Kassiou

Brief description Alzheimer's disease (AD) is the most prevalent dementia, characterized by progressive loss of memory. An estimated 230,000 Australians currently suffer from AD, causing a huge impact on their families and carers, as well as on national finances. The present therapies are very limited, and there is no cure. Thus, there is a need for novel treatment strategies. We have developed novel drugs that represent an innovative approach to the treatment of AD.

Funding Amount $AUD 629,260.47

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Help

Related Organisations

Related People

Subjects
Alzheimer's | Biochemistry and Cell Biology | Biological Sciences | Cell Neurochemistry | aging and dementia | alzheimer's disease | disease models, animal | drug design | drug discovery | macrophage activation | microglia | therapeutic target | transgenic animals |
Identifiers
Viewed: [[ro.stat.viewed]]
Saved to MyRDA Save to MyRDA